danavorexton danavorexton danavorexton (developmental code name tak-925) is a selective orexin 2 receptor agonist. it is a small-molecule compound and is administered intravenously. the compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial. as of march 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea. it is related to another orexin receptor agonist known as tak-994, the development of which was discontinued for safety reasons in october 2021. danavorextonclinical dataother namestak-925routes ofadministrationintravenousdrug classorexin receptor agonistidentifiers iupac name methyl (2r,3s)-3-(methanesulfonamido)-2-piperidine-1-carboxylate cas number2114324-48-8pubchem cid130310079chemspider68011464unii1qmd83k4ynchemblchembl4650341pdb liganda6f (pdbe, rcsb pdb)chemical and physical dataformulac21h32n2o5smolar mass424.56 g·mol−13d model (jsmol)interactive image smiles coc(=o)n1ccc(ns(c)(=o)=o)1co1cc(cc1)c1=cc=cc=c1 inchi inchi=1s/c21h32n2o5s/c1-27-21(24)23-14-6-9-19(22-29(2,25)26)20(23)15-28-18-12-10-17(11-13-18)16-7-4-3-5-8-16/h3-5,7-8,17-20,22h,6,9-15h2,1-2h3/t17-,18+,19-,20-/m0/s1key:uxzajszffartei-yrpnkdgesa-n